Search form
Search
contact us
Navigation
home
boards
Jobs
job ratings
cp wire
medtech news
pharmagather
catering
advertise
whistleblower info
pharmaceutical fraud
medical device | DME fraud
clinical lab fraud
False Claims Act
Legal Help
login/register
You are here
Home
» Pfizer says Phase 2b bococizumab study met primary endpoint across all doses
Pfizer says Phase 2b bococizumab study met primary endpoint across all doses
Pfizer says Phase 2b bococizumab study met primary endpoint across all doses
Submitted by
admin
on March 27, 2014 - 11:22am
Source:
The Fly on the Wall
News Tags:
Pfizer
bococizumab
RN316
cholesterol
Headline:
Pfizer says Phase 2b bococizumab study met primary endpoint across all doses
Do Not Allow Advertisers to Use My Personal information
